About this journal
Aims and scope
Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as:
- Preformulation and pharmaceutical formulation studies
- Pharmaceutical materials selection and characterization
- Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation
- QbD in the form a risk assessment and DoE driven approaches
- Design of dosage forms and drug delivery systems
- Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies
- Drug delivery systems research and quality improvement
- Pharmaceutical regulatory affairs
This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.
The journal's audience includes:
- Academic Researchers: Individuals involved in pharmaceutical research and development at universities and colleges.
- Industry Professionals: Experts working in the pharmaceutical industry, including formulation scientists, process engineers and quality assurance specialists.
- Healthcare Practitioners: Medical professionals interested in the latest advancements in drug delivery and pharmaceutical technologies.
- Policy Makers: Regulatory authorities and policy makers who oversee pharmaceutical practices and standards.
All articles received by the Journal will be subject to single-anonymous peer review.
Journal metrics
Usage
- 109K annual downloads/views
Citation metrics
- 2.6 (2023) Impact Factor
- Q2 Impact Factor Best Quartile
- 3.1 (2023) 5 year IF
- 5.9 (2023) CiteScore (Scopus)
- Q2 CiteScore Best Quartile
- 0.609 (2023) SNIP
- 0.476 (2023) SJR
Speed/acceptance
- 22 days avg. from submission to first decision
- 63 days avg. from submission to first post-review decision
- 13 days avg. from acceptance to online publication
- 15% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
EDITOR IN CHIEF
Professor Raid Alany
Kingston University
London
UK
SOCIAL MEDIA EDITORS
Ali Al-Kinani - Kingston University, UK
Arushi Manchanda - University of Connecticut, USA
BOOK REVIEW EDITOR
Harry Brittain - Center for Pharmaceutical Physics, Milford, NJ, USA
EDITORIAL BOARD
Zeeshan Ahmad - De Montfort University, Leicester, UK
Professor Göran Alderborn - Uppsala University Department of Pharmacy, Uppsala, Sweden
Professor Robin H. Bogner - University of Connecticut School of Pharmacy, Connecticut, USA
Dr.Gayle Brazeau - University of New England, Portland, ME, USA
Professor Craig Bunt - Lincoln University, Canterbury, New Zealand
Professor Carla Caramella - Universita degli Studi di Pavia, Pavia, Italy
Dr.Metin Celik - Pharmaceutical Technology International, Inc., Belle Meade, NJ, USA
Professor Yahya Choonara - University of the Witwatersrand, Johannesburg, South Africa
Professor/Dr. Tansel Çomoglu - Ankara University, Ankara, Turkey
Todd Darrington - Millennium Pharmaceuticals, Boston, MA, USA
Professor Gillian Eccleston - University of Strathclyde, Glasgow, Scotland, UK
David Friend - CONRAD, Arlington, VA, USA
Professor/Dr. Wolfgang Friess - Ludwig-Maximillians-Universitat, München, Germany
Professor/Dr. HW Frijlink - Groningen University, Groningen, Netherlands
Larry Gatlin - Consultant, Groton, CT, USA
Dr.Wayne Gombotz - Immune Design, Seattle, WA, USA
Associate Professor - Holger Grohganz - University of Copenhagen, Copenhagen, Denmark
Dr. Pramod Gupta - Spectrum, Irvine, CA, USA
Paul Heng - National University of Singapore, Singapore
Dr. Anthony Hickey - RTI International, Research Triangle Park, NC, USA
Professor Stephen Hoag - University of Maryland, Baltimore, MD, USA
Lars Hovgaard - Novo-Nordisk, Copenhagen Denmark
Munir Hussain - Bristol-Myers Squibb, New Brunswick, NJ, USA
Dr. Gerald Kasting - University of Cincinnati, Cincinnati, OH, USA
Professor Peter Kleinebudde - Heinrich-Heine-University, Düsseldorf, Germany
Jim Kou - Impax Labs, Hayward, CA, USA
Michael Leane - Bristol-Myers Squibb, Moreton, UK
Professor Kang Choon Lee - Sung Kyun Kwan University, Suwon City, South Korea
Professor Ping Lee - University of Toronto, Ontario, Canada
John Ludwig - Pfizer, Chesterfield, MO, USA
Dr. Rouslan I. Moustafine - Kazan State Medical University,Tatarstan, Russian Federation
Professor/Dr. Bernd Muller - Pharmazeutisches Institute, Kiel, Germany
Dr. Steve Nail - Baxter BioPharma Solutions, Bloomington, IN, USA
Professor/Dr. Ali Nokhodchi - University of Sussex, Brighton, UK
Katharina Picker-Freyer - Martin-Luther-Universitat, Halle/Saale, Germany
Stuart Porter - Hatfield, PA , USA
Dr. Omar Qutachi - De Montfort University, Leicester, UK
Professor Jukka Rantanen - University of Copenhagen, Copenhagen, Denmark
Professor/Dr. Jean-Paul Remon - Ghent University, Ghent, Belgium
Dr. Michael Repka - University of Mississippi, Oxford, MS, USA
Frantisek Rypacek - Institute of Macromolecular Chemistry, Prague, Czech Republic
Professor/Dr. Adel Sakr - Future University, New Cairo, Egypt
Dr. Claudio J Salomon - National University of Rosario, Rosario, Argentina
Professor Sevda Senel - Hacettepe Universtiy Faculty of Pharmacy, Ankara, Turkey
Professor Ali Seyfoddin - Auckland University of Technology, Auckland, New Zealand
Professor Jagdish Singh - North Dakota State University, Fargo, ND, USA
Paul J Sirois - Eli Lily and Company, Indianapolis, IN, USA
Dr. Eliana B. Souto - University of Coimbra, Porto, Portugal
Gregory A. Stephenson - Eli Lilly and Company, Indianapolis, IN, USA
Dr. Lynne Taylor - Purdue University, West Lafayette, IN, USA
Curt Thies- Thies Techology, Inc., Henderson, NV, USA
Dr. Mike Tobyn - Bristol-Myers Squibb, Moreton, England, UK
Dr. Thilini Thrimawithana - RMIT University, Melbourne, Australia
Murat Turkoglu - Markim Cosmetic Consultancy, Istanbul, Turkey
Ken Walters - The Old Coach House, Spraxton, UK
Dr. Ken Waterman - FreeThink Technologies, East Lyme, CT, USA
Dr. Zimei Wu - The University of Auckland School of Pharmacy, Auckland, New Zealand
Updated 02/07/24
Abstracting and indexing
id="_ctl0_ContentPlaceHolder1_HeaderDetails1_lblJournalTitle"> Pharmaceutical Development and Technology is included in the following abstracting and indexing services:
Biotechnology Abstracts; Business Source Corporate; Chemical Abstracts; Derwent Chimera; Derwent Drug File; International Pharmaceutical Abstracts; EMBASE; Journal Citation Reports/Science Edition; PASCAL; PopLine; PubMed/MedLine; SciSearch; SCOPUS.
Open access
Pharmaceutical Development and Technology is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Use our APC finder to calculate your article publishing charge
10 issues per year
Advertising information
Would you like to advertise in Pharmaceutical Development and Technology?
Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Pharmaceutical Development and Technology.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors